Skip to main content
SpringerLink
Log in

Vinorelbine-based regimens for NSCLC make pharmacoeconomic sense

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. American Cancer Society. Lung cancer 1998 facts & figures [online]. American Cancer Society; 1999. Available from: http://www.cancer.org/statistics/cff98/selectedcancers.html [Accessed 1999 Feb 22]

    Google Scholar 

  2. Kelly P, Clancy L. Is the use of chemotherapy justified in non-small cell lung cancer? Drugs Aging 1994 Jan; 4: 1–8

    Article  PubMed  CAS  Google Scholar 

  3. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997 Aug; 15: 2996–3018

    Google Scholar 

  4. Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. J Clin Oncol 1998 Dec; 16(12): 3900–12

    PubMed  CAS  Google Scholar 

  5. Shoheiber O, Schrogie JJ, Johnson N. Non-small cell lung cancer: a cost of illness study [abstract]. Pharmacotherapy 1996 Jan–Feb; 16: 136

    Google Scholar 

  6. Coukell AJ, Noble S, Faulds D. Vinorelbine in advanced non-small cell lung cancer. Pharmacoeconomics 1999 Apr; 15(4): 405–17

    Article  PubMed  CAS  Google Scholar 

  7. Le Chevalier T, Brisgand D, Douillard J-Y, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced nonsmall-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994 Feb; 12: 360–7

    PubMed  Google Scholar 

  8. Evans WK. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC. Oncology 1998 Mar; 12(3) Suppl. 4: 18–26

    PubMed  Google Scholar 

  9. Smith TJ, Hillner BE, Neighbors DM, et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995 Sep; 13: 2166–73

    PubMed  CAS  Google Scholar 

  10. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. Can Med Assoc J 1992; 146: 473–81

    CAS  Google Scholar 

  11. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993 Sep 15; 85(18): 1460–74

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vinorelbine-based regimens for NSCLC make pharmacoeconomic sense. Drugs Ther. Perspect 14, 13–16 (1999). https://doi.org/10.2165/00042310-199914040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199914040-00005

Keywords

Search

Navigation